Imiglucerase in the treatment of Gaucher disease: a history and perspective

Drug Design, Development and Therapy, 05/08/2012

The fortunes of the Genzyme Corporation, latterly acquired by global giant Sanofi SA, were founded on the evolution of a blockbuster therapy for a single but, as it turns out, propitious ultra–orphan disorder: Gaucher disease.

Print Article Summary Cat 2 CME Report